Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Vaccine
- Immune
- Cancer
- Disease
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 239032
License Grant
The University grants to Licensee and its Affiliates, a non-exclusive license under Licensed Patents to make, have made, use, import, sell, offer to sell, have sold the Licensed Products within the Licensed Field in the Licensed Territory.
License Property
The patents are titled Transfer Vectors and Microorganisms containing Human Cytomegalovirus (HCMV) Immediate-Early Promoter-Regulatory DNA Sequence.
Licensed Products shall mean and include any and all biological materials and products and processes the making, having made, using, selling or importing of which would, but for this Agreement, constitute an infringement of one or more Valid Claims of the Licensed Patents.
Field of Use
Licensed Field shall mean the use of the Licensed Patents in the production of proteins by cell culture. Licensed Field specifically excludes any use of the Licensed Patents or use and/or sale of Licensed Products for gene therapy applications and genetic immunization or DNA-based vaccines.
Licensee uses advances in biological sciences to discover, develop, manufacture and market products that treat or prevent infectious diseases, immune system disorders and cancer.
IPSCIO Record ID: 239014
License Grant
University hereby grants to Licensee and its Affiliates, subject to the terms and conditions hereof, a non-exclusive license under Licensed Patents to make, have made, use, import, have imported, sell, offer to sell and have sold the Licensed Products within the Licensed Field in the Licensed Territory.
License Property
Licensed Patents shall mean U.S. Patent Nos. 5,168,062 and 5,385,839 titled TRANSFER VECTORS AND MICROORGANISMS CONTAINING HUMAN CYTOMEGALOVIRUS (HCMV) IMMEDIATE-EARLY PROMOTER REGULATORY DNA SEQUENCE, by Prof. Mark F. Stinski, issued December 1, 1992 and January 31, 1995 respectively, or any U.S. patents issuing thereon, including any continuations, continuations-in-part, divisions, reissues, reexaminations and extensions thereof and patents corresponding thereto.
Licensed Products shall mean and include any and all protein or peptide based products or biological materials, including antibodies, or other processes and products in the Licensed Field, the making, using, selling or importing of which would, but for this Agreement, constitute an infringement of one or more Valid Claims of the Licensed Patents.
patents, commonly known as the CMV promoter patents, or Stinski patents, relating to the expression of recombinant proteins used in the manufacture of Aurexis.
Field of Use
Licensed Field shall mean the use of the Licensed Patents and the making, having made, using, selling or importing of the Licensed Products in the PRODUCTION OF PROTEINS by cell culture. Licensed Field specifically excludes any use of the Licensed Patents or use and/or sale of Licensed Products for gene therapy applications and including genetic immunization or DNA-based vaccines.
Aurexis is currently being evaluated in a Phase II clinical trial as a first-line therapy, in combination with standard of care antibiotics, to treat serious, life-threatening Staphylococcus aureus, or S. aureus, bloodstream infections in hospitalized patients.
Staphylococcus aureus is a Gram-positive, round-shaped bacterium that is a member of the Firmicutes, and it is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin.
IPSCIO Record ID: 369338
License Grant
Licensor, a private, not-for-profit clinical research center, hereby grants to Licensee and Licensee hereby accepts from Licensor, to the extent that each lawfully may do so, an exclusive, royalty-bearing right and license under the Patent Rights to make, have made, offer to sell, sell, use and import Licensed Products in the Field. No other license or rights under the Patent Rights or any other intellectual property of Licensor is granted or intended to be granted under this Agreement, either expressly, by implication, estoppel, or otherwise.
The rights granted by Licensor to Licensee shall become non-exclusive, at the option of Licensor, if (i) Licensee fails to perform.
Licensor shall retain all right, title, and interest in, to and under the Patent Rights except for the rights explicitly granted to Licensee in accordance with this Agreement.
Licensee shall have the right to sublicense non-exclusively the rights and/or licenses granted by Licensor to Licensee; provided, however, that (i) the sublicensee shall have no further right to grant sublicenses; (ii) the terms of any sublicense shall not be inconsistent with the terms of this Agreement; and (iii) Licensee promptly shall provide Licensor with a copy of each final sublicense agreement within ten (10) days after execution.
License Property
US 6,242,567 – Method for detection and prevention of human cytomegalovirus infection
US 6,133,433 – Method for detection and prevention of human cytomegalovirus infection
Patent Rights means, collectively, all right, title and interest of Licensor in, to and under (i) United States Patents Nos. 6,242,567, entitled “Method for detection and prevention of human cytomegalovirus infection†and 6,133,433, entitled “Method for detection and prevention of human cytomegalovirus infection,†(ii) all foreign counterparts of United States Patents Nos. 6,242,567 and 6,133,433; and (iii) any continuations-in-part, continuations, continued prosecution applications, divisionals, reexaminations reissues, or patent term extension patents claiming substantially the same technology as United States Patents Nos. 6,242,567 and 6,133,433.
Field of Use
TransVaxâ„¢ therapeutic vaccine for cytomegalovirus is for protection against CMV infection after stem cell transplants and protection against CMV infection after solid organ transplants
Cytomegalovirus (CMV) is a genus of viruses in the order Herpesvirales, in the family Herpesviridae, in the subfamily Betaherpesvirinae.
Field means all recombinant CMV vaccines containing or encoding molecules larger than fifty (50) amino acids, including DNA-based, viral-based and recombinant protein-based vaccines, and excludes diagnostics.
IPSCIO Record ID: 345562
License Grant
English Licensor granted a nonexclusive license to Licensee to produce and characterize potential product candidates using the Company’s viral vector technology and to provide research services to Licensee during the research term which commenced on June 2019 through the end of 66 months and for up to six vaccine products based on antigens discovered via Licensee’s proprietary platform.
License Property
Viral vector technology is known as ChAdOx1 and ChAdOx2. This platform comprises several components that, when combined, allow the developed product candidates designed to induce high and durable levels of antigen-specific T cells and B cells, to prevent and treat infectious diseases and cancer.
ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.
Field of Use
Field of use is for the immunotherapy and vaccine fields.
IPSCIO Record ID: 110461
License Grant
The University grants to Licensee and its Affiliates the exclusive license in the Territory with the right to grant sublicenses to others, under the Patent Rights, to make, have made, use, sell, import and offer for sale Products and to practice Processes.
Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.
License Property
The licensed patent applications relate to a Modified Heat Shock Protein-Antigenic Peptide Complex.
Field of Use
The licensed patent is in the area of the use of heat shock proteins for the development of therapeutic and prophylactic vaccines for cancer and infectious diseases (the 'Field').
IPSCIO Record ID: 248332
License Grant
Licensor grants to Licensee a non-exclusive license, with the right to grant sublicenses, under the Technology, and to use the Immune Modulator in connection therewith, in each case to make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Products in the Field in the Territory.
License Property
Licensor is the owner or licensee of certain rights, title, and interests in, and know-how related to, proprietary technologies involving immunomodulatory oligonucleotides.
Immune Modulator shall mean Coleys proprietary immunomodulatory oligonucleotide whose confidential sequence has been identified by Licensor as CpG 7909.
Licensed Product shall mean a product labeled for use in the Field and consisting of Immune Modulator, up to a maximum dose of 2 mg per administration, coformulated with one or more Antigens in a single vial; syringe or other suitable container.
VaxImmune™ is one member of Coley’s family of CpG TLR9 agonists, which are short synthetic DNA-like sequences that invoke potent innate and adaptive immune responses of the body’s immune system, comprised of both antibody- and cell-mediated pathways. Recent published scientific research by independent researchers have demonstrated that VaxImmune™ vaccine adjuvants are suitable for use in both prophylactic and therapeutic vaccines and can elicit a powerful immune response against infectious disease and cancers.
Field of Use
The Field shall mean the use of Immune Modulator co-formulated with one or more Antigens as a vaccine that is labeled solely for use as a prophylactic administered via a Specified Delivery Method to prevent one or more Specified Diseases in humans.
VaxImmune is known as a vaccine adjuvant, used in conjunction with a vaccine to improve immune responses and make the vaccine more effective.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
